Sino Biopharmaceutical Limited: Lymphoma trials

The registry lists 15 Lymphoma studies with Sino Biopharmaceutical Limited as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 13Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Phase 2
• The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic LymphomaNot yet recruitingNCT06434467Phase 3
• A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .RecruitingNCT05959694Phase 1/2
• To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory LymphomaStatus unknownNCT05400876Phase 1/2
• A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell LymphomaStatus unknownNCT04827004Phase 2
• A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）Status unknownNCT04615468Phase 2
• A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）Status unknownNCT04610970Phase 2
• A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride InjectionCompletedNCT04569838Phase 2
• A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Phase 2
• A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)Status unknownNCT04324879Phase 2
• A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)Status unknownNCT04306887Phase 2
• Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Phase 2
• Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
• Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaStatus unknownNCT03456466Phase 1/2